Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 26, 1999

View Archived Issues

Company Profile: HIV-VAC

Cel-Sci focuses clinical efforts on Multikine development

GenSci to form subsidiary focused on treatment of bone diseases

Sangamo and Schering AG enter research agreement for Universal GeneTools technology

Structural Bioinformatics receives SBIR grant for asthma treatment

FDA approves new emergency contraceptive product

Amylin acquires patent rights for exendin-4 gene

MacroChem awarded U.S. patent for Topiglan

MacroChem files US patent application for antifungal nail lacquer

Lilly launches reusable growth hormone delivery device for Humatrope

Roche Canada obtains licensing and marketing rights to TNK-tPA

Lundbeck establishes various collaborative agreements just after close of first half

Advances in the immunotherapy of cocaine abuse at Scripps Research Institute

Meiji Seika also shows interest in study of integrin receptor antagonists

NMI-377, an NO-donating diclofenac derivative with decreased GI side effects

Ferring's antidiuretic agent F-992 evaluated in healthy volunteers

British Biotech reports results of marimastat Study 145 in gastric cancer

Takeda and Lilly launch insulin sensitizer in first market, expand marketing relationship

Cytoskeleton employs novel HTS assay to identify new tubulin ligands

Berlin Chemie launches Sympal in Germany

Alcon suspends distribution of ophthalmic NSAIDs

Highlights from ACS: integrin antagonist SC-72115 is a potent angiogenesis inhibitor in vivo

P-SCN-Bz-HEHA, a bifunctional chelating agent designed to enable use of Ac-225 in radioimmunotherapy

German lab synthesizes new series of oxazolidinones

Bone resorption inhibitors, vitronectin receptor antagonists prepared at HMR

Celltech claims novel series of cell adhesion inhibitors

Chemokine receptor antagonists discovered through LeukoSite-Kyowa Hakko collaboration

Antiviral quinolinecarboxylic acid compounds reported by Sankyo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...